Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739513 | 1.00 | CYP1A2 (0.47) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL29399641 | 0.92 | CYP1A2 (0.52) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL1770875 | 0.92 | CYP1A2 (0.52) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL451039 | 0.85 | CYP1A2 (0.47) | CYP1A2ATMTDP1ALDH1A1HIF1A | |
| SCHEMBL12593915 | 0.84 | TDP1 (0.52) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL18905090 | 0.84 | TDP1 (0.52) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL7335 | 0.82 | ATM (0.55) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL1198631 | 0.82 | CYP1A2 (0.52) | CYP1A2TDP1ALDH1A1MAPTMEN1 | |
| SCHEMBL397387 | 0.82 | ATM (0.50) | CYP1A2ATMTDP1ESPL1ALDH1A1 | |
| SCHEMBL187542 | 0.82 | TDP1 (0.50) | CYP1A2ATMTDP1ESPL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| EP-4598927-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-07-03 | — | — | US | disclosed |
| CN-116113627-B | Ji Yin-dole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-119424423-A | 4-Aminobut-2-enamide derivatives and salts thereof | 大鹏药品工业株式会社 | 2025-02-14 | — | — | CN | disclosed |
| US-12187723-B2 | Substituted benzimidazolone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187723-B2 | Substituted benzimidazolone compounds | TLR7, TLR1, TLR9 | CYP1A2 2476/4885ATM 688/4885TDP1 1768/4885 |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | CYP1A2 649/4885ATM 3510/4885TDP1 1075/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | CYP1A2 4432/4885ATM 3350/4885TDP1 3050/4885 |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | CYP1A2 709/4885ATM 4400/4885TDP1 1439/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP1A2 146/4885ATM 3418/4885TDP1 4627/4885 |
| US-20060079683-A1 | Arylthiobenzylpiperidine derivatives | MCHR1, MC4R, MCHR2 | CYP1A2 530/4885ATM 3824/4885TDP1 903/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | CYP1A2 563/4885ATM 991/4885TDP1 1403/4885 |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | CYP1A2 203/4885ATM 3877/4885TDP1 3955/4885 |
| US-12453731-B2 | Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof | MLLT1, WDR77, MLLT3 | CYP1A2 1799/4885ATM 2397/4885TDP1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.